The expression levels of CD2, CD48, and CD58 were the lowest in the WHO II gliomas, and the highest in the WHO IV group, as shown in Table 1 and Figure 1A (p < .001), while there was no significant difference in CD59 expression between the WHO II–IV groups. This evidence concerns the gene CD59 and central nervous system cancer.